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Radix Sanguisorbae, the root of Sanguisorba officinalis L. is used as traditional
Chinese medicine. In recent decades, it has been reported to be clinically effective
against myelosuppression induced by chemotherapy and/ or radiotherapy. However,
the underlining mechanism has not been well studied. In this work, we evaluated the
hematopoietic effect of total saponins from S. officinalis L. on myelosuppressive mice
induced by cyclophosphamide and by60Co-γ-irradiation and confirmed the therapeutic
effect. Then, we found total saponins and their characteristic constituents Ziyuglycoside
I and Ziyuglycoside II can inhibit apoptosis of TF-1 cells caused by cytokine deprivation,
and promote survival of mouse bone marrow nuclear cells through focal adhesion kinase
(FAK) and extracellular signal-regulated kinase 1/2 (Erk1/2) activation in vitro. In addition,
they can down-regulate macrophage inflammatory protein 2 (MIP-2), platelet factor 4
(PF4) and P-selectin secretion, which are reported to be suppressive to hematopoiesis,
both in vitro and in vivo. These results suggest that promotion of survival through FAK
and Erk1/2 activation and inhibition of suppressive cytokines in the bone marrow is likely
to be the pharmacological mechanism underlying the hematopoietic effect of saponins
from S. officinalis L.
Keywords: myelosuppression, hematopoiesis, Sanguisorba officinalis L., saponin, Ziyuglycoside I, Ziyuglycoside
II, apoptosis, cytokine
INTRODUCTION
Patients receiving chemotherapeutic agents and/or ionizing radiation often experience varying
degrees of myelosuppression, characterized by the disruption of hematopoietic activity (Barreto
et al., 2014). Hematopoiesis is the production of various types of mature blood cells from
hematopoietic stem cells within the bone marrow. Antineoplastic agents display an indiscriminate
Abbreviations: BMNCs, bone marrow nucleated cells; BMSCs, bone marrow stromal cells; DMSO, dimethyl sulfoxide; EPO,
erythropoietin; Erk1/2, extracellular signal-regulated kinase 1/2; FAK, focal adhesion kinase; FBS, fetal bovine serum; GM-CSF,
granulocyte-macrophage colony stimulating factor; G-CSF, granulocyte colony-stimulating factor; IL-3, interleukin-3; MIP-
2, macrophage inflammatory protein 2; PF4, platelet factor 4; RLU, relative luminescence unit; SCF, stem cell factor; WBC,
white blood cells.
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toxicity to tumor cells and rapidly proliferating hematopoietic
progenitor cells (Parchment et al., 1998). The anti-tumor
therapy also causes myelotoxicity indirectly by affecting the
bone marrow microenvironment including stromal cells and
hematopoietic regulators in the bone marrow. Leukocytes have
the shortest half-life in circulation and a decrease in leukocytes
count (neutropenia) is a frequently occurring consequence of
myelosuppression. Profound myelotoxicity will lead to blood
losing events or severe infection presented with sepsis and febrile
neutropenia. Cancer treatment-induced hematologic toxicities
still are the main reasons of mortality and morbidity throughout
the therapy of cancer (Wang et al., 2006).
Granulocyte colony-stimulating factor is currently used as an
adjunct to chemotherapy for alleviating neutropenia. However,
there are some commonly reported side-effects associated with
administration of G-CSF including bone pain, flushing and
nausea (American Society of Clinical Oncology, 1994; Khoury
et al., 2000; Ozer et al., 2000).
Radix Sanguisorbae, the root of Sanguisorba officinalis L.,
is used to alleviate neutropenia in recent decades in China
(Liang et al., 2008). Radix Sanguisorbae is a well known herbal
medicine in China, Japan and Korea. It has hemostatic and
astringent properties (East, 1955), and is traditionally used in
clinical practice for the treatment of scalds-and-burns, bleeding,
diarrhea, duodenal ulcers, and chronic intestinal infections
(Zhang L. et al., 2012). The anti-inflammatory (Yu et al., 2011;
Ravipati et al., 2012), anti-infection (Liang et al., 2013; Liu et al.,
2014), antioxidant (Ravipati et al., 2012; Zhang L. et al., 2012),
anti-cancer (Cai et al., 2012; Choi et al., 2012), anti-allergic
(Kim et al., 2002; Park et al., 2004), anti-wrinkle (Kim et al.,
2008), and neuroprotective (Ban et al., 2008; Nguyen et al., 2008)
activities of extracts of S. officinalis L. roots or their bioactive
constituents have been reported. The bioactive constituents in
Radix Sanguisorbae include tannin, flavone, steroid, and saponin
compounds (Xia et al., 2009). Ziyuglycoside I and Ziyuglycoside
II are the characteristic constituents of saponin components
extracted from Radix Sanguisorbae. In additional to S. officinalis
L. roots which are used as Traditional Chinese Medicine in clinic,
a recent work by Szejk et al. (2017) reported the radioprotective
effects of the polyphenolic glycoconjugates from flowers of
S. officinalis L.
The clinical reports in recent decades demonstrated the
prophylactic effect of Radix Sanguisorbae on myelosuppression
induced by chemotherapy (Li et al., 2005) or radiotherapy
(Zhang R. et al., 2012). The therapeutic effect of Radix
Sanguisorbae against myelosuppression in patients was also
reported (Fu, 2014; Jiang et al., 2015). Moreover, no severe
side effects have been reported. The above clinical reports
suggest that Radix Sanguisorbae can enhance hematopoietic
recovery. Recent pharmacological studies in mice demonstrated
that saponin components from Radix Sanguisorbae are
major active constituents possessing hematopoietic effect.
Administration of the saponins increased the number of
bone marrow cells, leucocytes, erythrocytes, and platelets of
cyclophosphamide-induced myelosuppressive mice (Gao et al.,
2006). In the present study, we found that the total saponins
from S. officinalis L. roots can ameliorate myelosuppression
induced by cyclophosphamide and60Co-γ-irradiation on
mice. Ziyuglycoside I and Ziyuglycoside II (Figure 1A) are
the characteristic constituents of total saponins exacted from
S. officinalis L. roots (Cheng and Cao, 1992). We investigated the
effect of the total saponins, Ziyuglycoside I and Ziyuglycoside
II on hematopoietic cells and the secretion of cytokines by
using in vitro and in vivo assays. Our findings suggest that
the activation of FAK and Erk1/2, and modulation of cytokine
production may be the possible pharmacological mechanisms of
their hematopoietic activity.
MATERIALS AND METHODS
Reagents
Ziyuglycoside I and Ziyuglycoside II was supplied by Chengdu
Herbpurify Co., Ltd (China), dissolved in DMSO at the
concentration of 100 mg/ml. RPMI Medium 1640 and FBS
were obtained from Thermo Fisher Scientific Inc. Cell Titer-
Glo Luminescent Cell Viability Assay and Caspase-Glo 3/7 assay
system were purchased from Promega Biotech Co., Ltd. The
recombinant human G-CSF, (GM-CSF, EPO, and rmSCF), GM-
CSF, interleukin-3 (rmIL-3) were bought from ProSpec-Tany
Techno Gene Ltd. The inhibitor of FAK (PF 573228) and Erk1/2
(FR 180204) were obtained from Selleckchem.
Total Saponins Extraction and Isolation
The total saponins of Radix Sanguisorbae were prepared as
follows. In brief, air-dried roots of Sanguisorba officinalis L.
were purchased in the local market in Chengdu, China. One
kilogram of air-dried roots were sliced, and then reflux-extracted
with ethanol. After filtration, the ethanol extract was diluted
with 1.5 volume of distilled water and PH was adjusted to
10.5 by adding the alkaline solution (KOH) under stirring.
After centrifugation, the supernatant was subjected to HPD100
macroporous absorption resin and eluted using acetone. The
elution was evaporated under vacuum to yield the total saponins
from Radix Sanguisorbae. In the extract of total saponins, the
content of Ziyuglycoside I was 45∼50% (16.35∼18.17 mg/g
dry weight), and content of Ziyuglycoside II was 6∼8%
(2.18∼2.91 mg/g dry weight).
Animal Experiments
BALB/c mice, 6- to 8-week-old, were purchase from Da-suo
Bio-technology Limited (Chengdu, Sichuan, China). Kunming
mice, weighting 18–22 g, were supplied by Experimental Animal
Center of the Academy of Military Medical Sciences. Mice
were housed under controlled temperature and humidity and a
lighting cycle of 12 h/day. The mice were fed with untreated tap
water and commercial mice chow.
Cyclophosphamide was used to induce myelosuppression in
mice. The total saponins dissolved in saline were administered
orally for 14 day. Kunming mice were administrated (i.p.
injection) of cyclophosphamide at 100 mg/kg on Day 3 to 5.
On Day 12, peripheral blood was collected from tail veins for
determination of WBC.
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Irradiation was used to induce myelosuppression in mice.
A cobalt-60 γ-radiation source was used. Kunming mice were
placed in well-ventilated boxes and were irradiated of the whole
body at a single dose of 3.5Gy 60Co-γ irradiation on Day 1.
Rate of irradiation used was 1.27Gy per minute and the distance
between the source of irradiation and mice was 4 meters. Then
total saponins were administered orally for 14 day. Peripheral
blood WBC was analyzed on Day 13.
Cell Culture
Human bone marrow TF-1 cells (ATCC CRL-2003) were
maintained in RPMI 1640 supplemented with 10% FBS and
2 ng/mL of recombinant human GM-CSF until use. TF-1 cells
were used between passage 6 and 15.
Mouse BMNCs were harvested from femurs of 6- to 8-week-
old BLAB/c mice. Femora were dissected free of muscle and
connective tissue, and cut at one end under sterile conditions.
The marrow plugs were forced out with RPMI1640 (Invitrogen)
medium supplemented with 20% FBS, and filtered through a 75-
µM filter (Millipore). Then cells were rinsed with RPMI1640
medium and red blood cells were lysed with Tris-NH4Cl solution.
The erythrocytes- depleted BMNCs were kept in RPMI1640
medium with 20% FBS for further use.
Mouse BMSCs were isolated by their adherence to plastic.
Briefly bone marrow cells were collected by flushing the femurs
with RPMI1640 medium supplemented with 20% FBS. The
marrow plugs were filtered through a 75-µM filter (Millipore).
Cells were plated at a density of 2× 106cells in 6-well plates, and
the non-adherent cell population was removed after 72 h. The
medium was subsequently replaced twice weekly. The cells were
grown for 7–10 days until almost confluent.
Cell Viability Assay
Cells were seeded in 96-well plates and subjected to the saponins
treatment for indicated time periods. The viability of cells was
determined by ATP luminescent assay (Promega). In brief,
equilibrate the plate at room temperature for approximately
30 min, then add a volume of CellTiter-Glo reagent equal to the
volume of cell culture medium present in each well. Mix contents
for 2 min on an orbital shaker to induce cell lysis, and allow the
plate to incubate at room temperature for 10 min then record
RLU.
% Growth = (RLU sample− RLU control)/
RLU control× 100. (1)
Caspase3/7 Activity Assay
TF-1 cells were maintained in culture medium free of GM-CSF
2 days before saponins treatment. Then cells were seeded at a
density of 1.5 × 104 cells in 96-well plates in the presence or
absence of saponins for 48 h. The activities of caspase-3 and -7
were detected by luminescent assay (Promega). Briefly equilibrate
the plate at room temperature for approximately 30 min, then
add 100 µL Caspase-Glo 3/7 reagent to each well of cells in equal
volume of culture medium. Mix contents for 30 s, and incubate at
room temperature for 1 h then record luminescence.
Western Blot Analysis
TF-1 cells were seeded at a density of 5 × 106 cells in 6-well
plates, and treated with saponins or DMSO over a period of
24 h. To measure the phosphorylation of Erk1/2 protein, mouse
BMNCs were seeded at a density of 1 × 107 cells in 6-well
plates and treated with or without saponins for different times.
Whole cell protein was extracted using a Total Protein Extraction
Kit (CWBiotech). Protein concentration in the supernatant was
determined by a BCA protein assay (Bio-Rad). Equal amounts
of protein were loaded on an SDS-poly-acrylamide gel and
transferred to a PVDF membrane (Millipore) before blocking
with 5% nonfat dried milk in PBS with 0.1% Tween-20. Primary
and secondary antibodies were diluted in blocking solution.
Primary antibodies used in this study were bcl-2, bcl-xl, Mcl-1,
survivin, Bax, Bim, pErk1/2 (Cell Signaling Technology). Bound
primary antibodies were detected with SuperSignal Western Blot
Substrate (Thermo scientific).
Immunoprecipitation and In vitro Kinase
Assay
For the immunoprecipitation studies, saponins-stimulated, or
unstimulated mouse BMNCs were lysed in ice-cold lysis buffer
(Cell Signaling Technology) adding 1 mmol/L PMSF. Lysates
were precleared with rabbit isotype control (Cell Signaling
Technology) and protein G plus/protein A agarose beads
(Millopore) for 1 h at 4◦C. After removal of agarose beads by
brief centrifugation, protein concentration in the supernatant
was determined and the precleared lysates were incubated with
anti-pFAK (p576/577) overnight at 4◦C. The immunocomplexes
were captured by incubation for 3 h at 4◦C with protein G/A
agarose beads. Immunoprecipitates were washed three times with
phosphate-buffered saline, two times with kinase reaction buffer
A (Promega). Bound proteins were resuspended in 25 µL kinase
assay buffer, and phosphatase activity of immunoprecipitated
FAK was assessed using a FAK kinase assay (Promega) following
the manufacturer’s instructions. FAK activity was normalized
with respect to the total protein content of cell lysates.
Cytokine Arrays
Mice were treated with total saponins and/or cyclophosphamide
as described in Section “Animal Experiments”. Mice were killed
by cervical dislocation and the femurs were dissected free of
muscle and tendons, and then marrow was extruded by flushing
the shaft of the bone with 0.5 ml of RMPI1640 supplemented
with 20% FBS. The resulting cell suspension was filtered through
a 75-µM filter and particulates were removed by centrifugation.
The mouse cytokine antibody array (Ray Biotech) was used to
study the expression profile of cytokine proteins in the clarified
supernatant following the manufacturer’s instructions.
Confluent primary mouse BMSCs were seeded at a density of
25 × 104 cells and grown in 24-well plates in a final volume of
1 mL culture medium per well. After 24 h, the cells were treated
with total saponins or vehicle control over a period of 24 h. The
cytokines in the cell culture supernatant were evaluated using the
cytokine antibody array as mentioned above.
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Cytokine ELISA
Confluent primary mouse BMSCs were seeded at a density of
8 × 104 cells and grown in flatbottomed96-well plates in a final
volume of 200 µL culture medium per well. After 24 h, the cells
were treated with saponins or DMSO over a period of 24 h. The
culture supernatant of control and treated cells were collected
for measurement by centrifugation to remove particulates. The
level of PF4, MIP-2, and sP-Selectin in supernatant was measured
using the enzyme-linked immunoassay kit (R&D Systems)
according to the protocol of the manufacturer. The results were
normalized to the cell number of BMSCs.
Co-culture
Confluent primary mouse BMSCs were seeded in the 24-well
plates at a density of 25 × 104 cells in a final volume of 1 mL
culture medium per well. After 24 h, the cells were treated with
saponins or DMSO over a period of 6 h. Then fresh medium
was added following removal of drugs. Mouse BMNCs were
seeded into the cell culture insert (Falcon, BD Bioscience) at
a concentration of 7 × 105 cells, and co-cultured with the
pretreated mouse BMSCs monolayer. Cells were harvested after
48h, the viability of cells was assessed using ATP luminescent
assay as described above.
Statistical Analysis
Values were given as mean ± standard deviation of at least three
independent experimental replications. Comparisons between
mean values were made using one way ANOVA with a Fisher’s
LSD test, and p < 0.05 was determined to indicate statistical
significance.
RESULT
Total Saponins from S. officinalis L.
Enhanced Hematopoietic Recovery in
Myelosuppression Mouse Model
Compared to the vehicle control group, the injection of
cyclophosphamide and irradiation of 60Co-γ decreased WBC
dramatically (p < 0.001), as indicated in Figure 1. The
hypodermic injection of rhG-CSF alleviated neutropenia
significantly (p < 0.001), compared to the group treated with
cyclophosphamide or 60Co-γ alone. The oral administration of
total saponins either 1.6 mg/kg or 0.8 mg/kg for 7 days following
chemotherapy increased WBC significantly (p < 0.001),
compared to the group treated with cyclophosphamide alone
(Figure 1B). Administration of total saponins at 1.6, 0.8,
and 0.4 mg/kg increased WBC of cyclophosphamide treated
mice from 6.1 ± 1.5 × 103/µL to 10.5 ± 3.3, 10.4 ± 4.1, and
7.9 ± 2.0 × 103/µL, respectively. The oral administration
of total saponins either 1.6 mg/kg or 0.8 mg/kg for 13 days
following radiotherapy alleviated neutropenia significantly
(p < 0.05) (Figure 1C), compared to the group treated with
60Co-γ exposure alone. Administration of total saponins at
1.6, 0.8, and 0.4 mg/kg increased WBC of 60Co-γ irradiated
mice from 4.2 ± 0.59 × 103/µL to 6.5 ± 1.57, 6.4 ± 1.26 and
5.9± 1.17× 103/µL, respectively.
Saponins from S. officinalis L. Promoted
Survival of Bone Marrow Cells In vitro
We investigated the effect of total saponins from S. officinalis L.
roots and their characteristic constituents Ziyuglycoside I and
Ziyuglycoside II on the viability of bone marrow cells in vitro.
Bone marrow hematopoietic cells are hematopoietic cytokine
dependent in the in vitro culture and we performed the assay in
the presence and absence of hematopoietic cytokines.
Mouse BMNCs were prepared and cultured with saponins for
6 days. We found that in the cytokine free group, treatment with
total saponins, Ziyuglycoside I and Ziyuglycoside II resulted in a
dose-dependent increase in cell viability by up to 73% (±28%),
22% (±9%), and 63% (±11%), respectively, as compared to
vehicle-treated control cells, whereas in the presence of cytokines
in the medium (a mixture of GM-CSF, SCF, IL-3, EPO, which
are commonly used to support hematopoietic progenitor cells
in the in vitro culture), treatment by saponins exhibited little
improvement in cell viability as compared to vehicle-treated
control (less than10%) (Figure 2A).
TF-1 is a bone marrow-derived human hematopoietic
progenitor cell line and we also used them to evaluate the effect
of saponins. TF-1 cells are cytokine dependent and are normally
cultured in medium supplemented with GM-CSF. Under such
culture condition, treatment by saponins (48 h) had little effect
on cell viability as compared to vehicle-treated control (less
than10%). In the cytokine free group cells were depleted of GM-
CSF 48h before saponins stimulation. Treatment of cytokine-
deprived TF-1 cells with total saponins, Ziyuglycoside I and
Ziyuglycoside II (48 h) induced up to a 70% (±11%), 24%
(±8%), and17% (±5%) increase in cell viability, respectively,
as compared to vehicle-treated control (Figure 2B). These data
demonstrated that total saponins from S. officinalis L. roots,
Ziyuglycoside I and Ziyuglycoside II were able to promote
survival of bone marrow cells in vitro.
Saponins from S. officinalis L. Exerted
Anti-apoptotic Effects on TF-1 Cells
As shown above, saponins from S. officinalis L. roots enhanced
the survival of cytokine-deprived TF-1 cells. It has been reported
that cytokine deprivation in TF-1 cells induced apoptosis (Lin
et al., 2007). Consequently, we tested the anti-apoptotic effect
of the saponins, by measuring the activity of caspase-3 and -
7 which are downstream effector caspases executing apoptosis.
Consistent with other reports, GM-CSF withdrawal for 48h
increased caspase-3 and -7 activities by 7 times the complete
medium control (Figure 3A). The high levels of caspase-3
and -7 activities induced by cytokine deprivation were reduced
by saponins treatment in a dose-dependent manner. Treating
cytokine-deprived TF-1 cells with total saponins, Ziyuglycoside
I, and Ziyuglycoside II (48 h) inhibited caspase-3 and -7 activities
up to 39% (±11%), 27% (±6%), and 26% (±8%), respectively,
as compared to vehicle-treated control (Figure 3B). Then, we
detected the protein level of anti-apoptotic protein survivin and
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FIGURE 1 | Total saponins enhanced hematopoietic recovery in myelosuppression mouse model. (A) Ziyuglycoside I and ziyuglycoside II. (B) Peripheral
blood WBC analysis on Day 7 after the injection of 100 mg/kg cyclophosphamide. ###p < 0.001 compared to vehicle control, ∗∗∗p < 0.001 compared to
cyclophosphamide. (C) Peripheral blood WBC analysis on Day 13 after the 3.5Gy 60Co-γ irradiation. ###p < 0.001 compared to vehicle control, ∗p < 0.05
∗∗∗p < 0.001 compared to 60Co-γ. Data were presented as mean ± SD (n = 13).
several Bcl-2 family members including anti-apoptotic bcl-2,
bcl-xl, Mcl-1, and pro-apoptotic Bim and Bax. We found that
saponins treatments increased the protein expression of anti-
apoptotic Mcl-1 and survivin (Figure 3C) in GM-CSF deprived
TF-1 cells and other proteins we tested were not affected. These
data suggested that up-regulation of Mcl-1 and survivin by
saponins was involved in their anti-apoptosis effect on cytokine-
deprived TF-1 cells.
Activation of FAK and Erk1/2 was
Involved in the Pro-survival Effect of
Saponins from S. officinalis L. on Bone
Marrow Cells
From our previous work (data not shown), we speculated that
total saponins from S. officinalis L. roots could activate FAK
and Erk1/2. In this study, we confirmed that treatment of total
saponins, Ziyuglycoside I and Ziyuglycoside II elevated activity of
FAK and Erk1/2 on bone marrow cells. As shown in Figure 4A,
we measured kinase activity of FAK by in vitro kinase assay
after immunoprecipitated with anti-pFAK (p576/577) antibody
and we found that the tyrosine phosphorylation-associated FAK
kinase activity was enhanced at 2 h after saponins treatment
in a dose-dependent manner. Treatment with total saponins,
Ziyuglycoside I and Ziyuglycoside II induced up to a 112, 180,
and 83% increase in pFAK activity, respectively, as compared
to vehicle-treated control. As shown in Figure 4, western blot
analysis using anti-pERK1/2 antibody showed that levels of
phosphorylation of Erk1/2 increased after saponins stimulation
at later time points (Figure 4B, 16 h∼24 h for total saponins and
Ziyuglycoside I, and 6 h∼24 h for Ziyuglycoside II) in a dose
dependent manner (Figure 4C).
To investigate whether the pro-survival effect of saponins
was mediated through FAK and Erk1/2 activation, the inhibitor
of FAK (PF 573228) and Erk1/2 (FR 180204) were used in
combination with the saponins. As shown in Figure 5, different
dose of PF 573228 (Figure 5A) or FR 180204 (Figure 5B)
alone had no obvious influence on cell viability, while both of
them effectively suppressed the pro-survival effect of saponins
on bone marrow cells in a dose-dependent manner. When
total saponins (100 µg/mL) was used in combination with PF
573228 (2, 1, 0.5 µM), the increase in cell viability reduced
from 84 to 12%, 38 and 53%, respectively. While FR 180204
(5, 2.5, 1.25 µM) was used in combination with total saponins
(100 µg/mL), the increase in cell viability reduced from 126
to 90%, 101 and 105%, respectively. When Ziyuglycoside II
(30 µg/mL) was used in combination with PF 573228 (2, 1,
0.5 µM), the increase in cell viability reduced from 66 to 4%,
5 and 22%, respectively. While FR 180204 (5, 2.5, 1.25 µM)
was used in combination with total saponins (30 µg/mL), the
increase in cell viability reduced from 66 to 32%, 45 and 47%,
respectively.
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FIGURE 2 | Saponins from Sanguisorba officinalis L. promoted survival of bone marrow cells. (A) Mouse BMN cells were maintained in medium free of
cytokine or complete medium (containing 50 ng/mL rmSCF, 10 ng/mL rmIL-3, 10 ng/mL rmGM-CSF, 3 U/mL Epo). Mouse BMNCs were seeded at a density of
7 × 105 cells in 96-well plates in the presence or absence of saponins for 6 days. (B) TF-1 cells were cultured in medium free of GM-CSF 2 days before saponins
treatment or complete medium (containing 2 ng/mL rhGM-CSF). TF-1 cells were seeded at a density of 1.5 × 104 cells in 96-well plates and stimulated with
saponins for 48 h. All experiments were repeated at least three times. Data were presented as mean ± SD.
Saponins from S. officinalis L. Reduced
Suppressive Cytokines in Bone Marrow
Microenvironment
Cytokines in the bone marrow microenvironment play vital
roles in the regulation of hematopoiesis. So, we investigated
the effect of total saponins from S. officinalis L. roots on bone
marrow microenvironment in vivo and in vitro by performing a
mouse cytokine antibody array. As a model of myelosuppression,
mice were injected with cyclophosphamide, and then, were co-
administrated with either total saponins or vehicle as described
in Section “Animal Experiments”. The mouse bone marrow
supernatant fluid were collected and measured for cytokine
expression. Compared to the myelosuppression group, Levels
of seven cytokines (MIP-1-γ, MIP-2, PF4, RANTES, sTNF
RI, sTNF RII, and P-selectin) reduced in the total saponins
treatment group compared to the control myelosuppression
group. BMSCs secrete various cytokines into the bone marrow.
So, we also isolated BMSCs and measured their cytokine
expression after total saponins stimulation. Level of thirteen
cytokines (CXCL16, IFN-γ, IL-3, IL-4, IL-6, IL-12-p70, MIG,
MIP-2, MIP-3α, PF4, P-selectin, VCAM-1, VEGF) decreased and
two (BLC, Eotaxin-2) increased in cell culture supernatant of
BMSCs after total saponins treatment (treatment/ control >1.2
or <0.8).
The expression of MIP-2, PF4, and P-selectin reduced after
total saponins treatment both in the in vivo and in vitro study
(Figure 6A). According to previous reports, these three cytokines
are negative regulators of hematopoiesis. To validate the array
data, we measured their protein levels on primary mouse BMSCs
treated with different dose of total saponins, Ziyuglycoside I and
Ziyuglycoside II by performing ELISA assay. Compared with
untreated cells, saponins treatment for 24 h reduced the protein
level of MIP-2 and PF4 in cell culture supernatant in a dose-
dependent manner (Figure 6B). Treatment with total saponins,
Ziyuglycoside I and Ziyuglycoside II resulted in up to 62, 67,
and 65% inhibition of MIP-2 protein expression, respectively,
and 52, 36, and 15% reduction of PF4 protein level, respectively,
as compared to vehicle-treated control. We could not detect
P-selectin in the cell culture supernatant using ELISA method.
This may be because the content of P-selectin in cell culture
supernatant may be under the minimum detectable dose of our
method.
To assess how bone marrow cell growth was affected by
the reduction of hematopoiesis negative regulators caused by
saponins treatment, we performed co-culture experiments using
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FIGURE 3 | Saponins from S. officinalis L. exerted anti-apoptotic effects on TF-1 Cells. (A–B) The activity of caspase3/7 in TF-1 cells. Assays were done in
triplicate. Mean values with standard deviations are shown. (C) Change of protein expression patterns in TF-1 cells. Cells were cultured in medium free of GM-CSF
for 2 days. Then cells were treated with saponins or vehicle for 48 h. Representative results of three independent experiments are shown.
mouse BMSCs and primary bone marrow cells (BMNCs). Mouse
BMSCs were pretreated with different dose of total saponins,
Ziyuglycoside I and Ziyuglycoside II, and then co-cultured
with BMNCs in the upper inserts. Compared with untreated
control, saponins-pretreatment increased the viability of BMNCs
co-cultured (Figure 6C). Pretreatment with total saponins,
Ziyuglycoside I and Ziyuglycoside II (6 h) induced up to a 29,
21, and 21% increase in cell viability, respectively, as compared
to vehicle-treated control. These results indicated that saponins
of S. officinalis L. roots could improve the survival of BMNCs
by reducing secretion of hematopoiesis negative cytokines from
BMSCs.
DISCUSSION
The extract of S. officinalis L. roots has been reported to have
therapeutic effect on chemotherapy- and radiotherapy-induced
neutropenia in clinic in China. However, the mechanism of its
therapeutic effect on neutropenia has not been reported yet. In
this study, firstly we assessed the effect of total saponins from
S. officinalis L. roots on myelosuppression mouse models and
demonstrated that total saponins accelerated the hematopoietic
restoration after injury induced by cyclophosphamide and60Co-
γ-irradiation. This result is consistent with the clinical findings of
the therapeutic effects of S. officinalis L. roots on neutropenia.
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FIGURE 4 | Saponins from S. officinalis L. induced activation of FAK and ERK1/2. (A) In vitro kinase assay for tyrosine phosphorylation-associated FAK
kinase activity. The assay was performed in triplicate. Data were presented as mean ± SD. (B–C) Western blotting analysis for ERK1/2 phosphorylation. The time
point was 16h in (C). Representative results of three independent experiments are shown.
FIGURE 5 | The inhibitor of FAK and Erk1/2 suppressed the pro-survival effect of saponins on bone marrow cells. (A) Viability of mouse BMN cells
treated with PF 573228 (inhibitor of FAK), either alone or in combination with saponins. (B) Viability of mouse BMN cells treated with FR 180204 (inhibitor of Erk1/2),
either alone or in combination with saponins. The experiment was repeated at least three times. Data were presented as mean ± SD.
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FIGURE 6 | Saponins from S. officinalis L. inhibited suppressive cytokine production. (A) Mouse cytokine antibody array showing fold change in gene
expression patterns of MIP-2, PF4, and P-selectin in bone marrow and conditioned medium of BMSCs. To collect sample of bone marrow, mice were treated with
total saponins and cyclophosphamide as described in Section “Animal Experiment”, and mouse bone marrow supernatant fluid was collected as mentioned in
Section “Cytokine Arrays”, and cyclophosphamide treatment alone was used as control (n = 8). The conditioned medium of BMSCs was collected as mentioned in
Section “Cytokine Arrays”, and vehicle treatment was used as control. The fold change value is calculated by dividing the data from treatment with control. (B) ELISA
analysis for MIP-2 and PF4 in cell culture supernatant of mouse BMSCs. (C) Viability of mouse BMN cells co-cultured with BMSCs pretreated with saponins. The
experiment was repeated at least three times. Data were presented as mean ± SD.
Ziyuglycoside I and ziyuglycoside II are the characteristic
constituents of total saponins from S. officinalis L. roots. To
further reveal the role of total saponins in the regulation of
hematopoiesis, we then investigated the effect of total saponins
and their characteristic constituents on the growth of bone
marrow cells. We used primary bone marrow cells (BMNCs)
and cytokine-dependent TF-1, which is a human hematopoietic
progenitor cell line with CD34+ phenotype (Civini et al., 2013), to
carry out the study. We found that in cytokine-free medium total
saponins, Ziyuglycoside I and Ziyuglycoside II greatly increased
cell viability compared with the vehicle-treated control. Using
cytokine-deprived TF-1 cells as apoptosis model, we found that
total saponins, Ziyuglycoside I and Ziyuglycoside II can reduce
apoptosis caused by cytokine deprivation and anti-apoptotic
proteins Mcl-1 and survivin were involved in the anti-apoptotic
effect of saponins. We further investigated pathways involved in
the pro-survival effect of saponins on bone marrow cells.
Focal adhesion kinase is a nonreceptor protein tyrosine kinase,
transducing signals from integrins, some cytokines, and growth
factor receptors. It is expressed in many hematopoietic cells,
including granulocyte macrophage progenitor cells, erythroid
progenitors and lymphoid cells, etc. (Choi et al., 1993; Kume
et al., 1997). Activation of integrins or cytokine receptors
interacted induces rapid phosphorylation on tyrosine residue
397 of FAK and subsequent phosphorylation of tyrosine residue
576/577 in activation loop of FAK, which results in full catalytic
activity (Lietha et al., 2007). To test whether the saponins from
S. officinalis L. roots could activate FAK, we immunoprecipitated
phospho-FAK (Tyr576/577) from both vehicle- and saponins-
treated mouse BMNCs lysates, followed by in vitro kinase assay,
and found that saponins treatment increased the kinase activity
of FAK. It has been reported that FAK play a crucial role
in regulating stress hematopoiesis (Vemula et al., 2010) and
hematopoietic cell lodgment and lineage development (Glodek
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et al., 2007). In the current study, we found that saponins induced
survival enhancement of bone marrow cells could be blocked by
inhibition of FAK activity using the FAK inhibitor PF 573228.
These results indicated the involvement of FAK activation in the
improvement of cell survival after saponins treatment.
Extracellular signal-regulated kinase are serine/threonine
kinases that play critical roles in regulation of cell growth,
proliferation and survival (Geest and Coffer, 2009). It has
been demonstrated that ERK1/2 signaling is involved in the
normal hematopoiesis (Staser et al., 2013), and is important
in maintaining hematopoietic homeostasis (Chung and Kondo,
2011). We performed Western blot assay to detect the
phosphorylation of ERK1/2, and found that saponins treatment
up-regulated the phospho-ERK. In addition, the survival
enhancement of bone marrow cells in response to saponins was
blocked by ERK1/2 inhibitor FR 180204, indicating that saponins
may improve the survival of bone marrow cells through ERK1/2
activation.
The bone marrow microenvironment plays a vital role in
hematopoiesis. Hematopoietic growth factors, cytokines and
chemokines in the microenvironment secreted by BMSCs
regulate the development of hematopoietic cells (Majka et al.,
2001). We monitored the levels of 62 cytokines in cultured
mouse BMSCs treated with total saponins, using a mouse
cytokine antibody array. The levels of cytokines in bone marrow
of mice were determined using the same array. Reduced
expression of PF4, MIP-2, and P-selectin was observed both
in the conditioned medium of total saponins-treated mouse
BMSCs, and in the bone marrow of total saponins-treated
myelosuppressive mice.
PF4 is a member of the C-X-C chemokine family. It is not
a potent chemotaxin agent (Deuel et al., 1981; Petersen et al.,
1996), but strongly inhibits hematopoiesis (Lecomte-Raclet et al.,
1998). PF4 has been reported to be able to suppress colony
formation of early committed myeloid progenitor cells at low
concentrations in the nanomolar range in vitro (Broxmeyer et al.,
1993), and inhibit proliferation of human CD34+ hematopoietic
progenitor cells (Dudek et al., 2003). In the study of PF4
knockout mice and transgenic mice overexpressing human
PF4, platelet count and megakaryocyte colonies were inversely
associated with PF4 content, and treatment with anti-PF4
blocking antibodies accelerated the recovery of 5-Fu-induced
marrow failure, especially in PF4-overexpressing mice (Lambert
et al., 2007).
The myelosuppressive effects of MIP-2 and P-selectin
on hematopoiesis has been described by other researchers
(Broxmeyer et al., 1995; Eto et al., 2005). Mouse MIP-2
is classified as a member of the C-X-C chemokine family,
and it is homolog of human MIP-2α based on the protein
sequence similarity. MIP-2α has been reported to be suppressive
to immature subsets of stem and progenitor cells in vitro
(Broxmeyer et al., 1993). P-selectin is cell adhesion molecule,
which is involved in the interaction between hematopoietic
progenitor cells and the stromal cell in the bone marrow
microenvironment. P-selectin could inhibit the proliferation
of human and mouse hematopoietic progenitor cells in vitro
(Levesque et al., 1999), and mice deficient for both P- and
E-selectin presented enhanced hematopoiesis (Frenette et al.,
1996).
Treatment with total saponins reduced the level of MIP-
2, PF4, and P-selectin in both bone marrow of mice and cell
culture supernatant of mouse BMSCs. ELISA results further
validated that total saponins, Ziyuglycoside I and Ziyuglycoside
II suppress the expression of MIP-2 and PF4 dose-dependently.
To study whether saponins of S. officinalis L. roots could affect
hematopoiesis by reducing secretion of suppressive cytokines,
we co-cultured BMNCs with BMSCs pretreated with saponins.
The result confirmed that saponins of S. officinalis L. roots
could influence hematopoietic microenvironment by modulating
cytokine production of BMSCs, and thus promoted survival of
BMNCs co-cultured.
Ziyuglycoside I is the glucopyranose ester of Ziyuglycoside
II. In the present study, we observed activity difference between
Ziyuglycoside I and II in vitro. Treatment with Ziyuglycoside I
(25µg/mL) induced 166% increase in pFAK kinase activity, while
Ziyuglycoside II (30 µg/mL) induced 83% increase compared to
vehicle-treated control (Figure 4A). The level of phosphorylation
of Erk1/2 increased 6 h after Ziyuglycoside II (30 µg/mL)
stimulation, while obvious increase of pErk1/2 could not be
observed until 16 h after Ziyuglycoside I (80 µg/mL) stimulation
(Figure 4B). The structure-activity relationship of Ziyuglycoside
I and II require further studies.
Dozens of saponins have been identified in extracts of S.
officinalis L. roots and most of them are triterpenoid saponin
(Cheng and Cao, 1992; Mimaki et al., 2001; Liu et al.,
2005). Ziyuglycoside I and ziyuglycoside II are characteristic
constituents of S. officinalis L. roots and various bioactivities
of them have been studied. Kim and their colleagues reported
the anti-wrinkle activity of Ziyuglycoside I by increasing type
I collagen expression in fibroblast cells and its application as
anti-wrinkle cosmeceutical ingredient (Kim et al., 2008). Radix
Sanguisorbae is traditional used as a hemostatic agent in clinic
and Ziyuglycoside I was reported to have hemostatic activity by
effecting α2-plasmin inhibitor (Sun et al., 2012). Ziyuglycoside
I was reported to have anti-cancer effect in a breast cancer
cell line through up-regulation of p53 and p21 (Zhu et al.,
2016) and Ziyuglycoside II was reported to have anti-cancer
activity by induction of reactive oxygen species (ROS) and ROS
dependent apoptotic pathways in tumor cell lines (Zhu et al.,
2014). But there is not clinical practice of using S. officinalis L.
or its bioactive constituents as anti-cancer agents, and there is
little information available about toxicological studies of saponins
from S. officinalis L.. These reports suggested that Ziyuglycoside I
and ziyuglycoside II can exert various biology effects by activating
different pathways in different cells. In the present work, we
found that Ziyuglycoside I, Ziyuglycoside II, and total saponins
can promote survival of bone marrow cells through activating
FAK and Erk1/2 pathways and they can also reduce suppressive
cytokines MIP-2 and PF4 in BMSCs. Their ability to interact
with these pathways and cytokines has never been discovered
before. Our work investigates the underlining mechanisms of
hematopoietic effect of saponins from S. officinalis L. roots for
the first time and provides scientific supports to the clinical use
of S. officinalis L. for the treatment of myelosuppression.
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CONCLUSION
Clinical practice in recent decades in China demonstrated that
the extract of S. officinalis L. roots can increase WBC counts
and alleviate myelotoxicity caused by anti-neoplastic therapy.
However, the underlining mechanism has not been reported yet.
In the present study, we evaluated and confirmed the therapeutic
effect of total saponins from this plant in myelosuppressive mice.
We found that total saponins and their characteristic constituents
Ziyuglycoside I and Ziyuglycoside II can increase the expression
of anti-apoptotic protein Mcl-1 and survivin in cytokine-depleted
TF-1 cells, inhibit apoptosis of these cells and promote survival of
mouse BMNCs cultured in cytokine-deprived medium through
FAK and Erk1/2 activation. Furthermore, saponins-treatment
reduced the levels of some suppressive cytokines both in vitro
and in vivo. Our findings suggest that saponins from S.
officinalis L. roots improve hematopoiesis by promoting survival
through FAK and Erk1/2 activation and modulating cytokine
production in the bone marrow. The present study provides
scientific supports to the clinical use of S. officinalis L. roots
for the treatment of myelosuppression. We hope this work
will benefit the development of new therapeutic agents against
myelosuppression.
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